FDA will consider Moderna's mRNA flu vaccine after all - Summary - MDSpire

FDA will consider Moderna's mRNA flu vaccine after all

  • By

  • Lauran Neergaard

  • February 18, 2026

  • 0 min

Share

Objective:

To assess the FDA's decision to review Moderna's mRNA influenza vaccine application after a previous dispute regarding trial design and safety concerns.

Key Findings:
  • The FDA is set to make a decision by August 5.
  • Moderna's shares increased by 6% following the announcement.
  • The vaccine has also been submitted for approval in Europe, Canada, and Australia.
  • The FDA's review reflects heightened scrutiny of mRNA vaccines under the current health administration.
Interpretation:

The FDA's review process reflects ongoing scrutiny of mRNA vaccines under the current health administration, indicating a cautious approach to new vaccine approvals, potentially influenced by political factors.

Limitations:
  • The FDA's refusal to file was based on the trial's design, which may limit the vaccine's initial approval scope and affect public trust.
  • The public dispute highlights potential political influences on FDA decision-making, raising concerns about the integrity of the review process.
Conclusion:

Moderna's mRNA influenza vaccine may soon be available, pending FDA approval, amidst a backdrop of heightened regulatory scrutiny.

Original Source(s)

FDA will consider Moderna's mRNA flu vaccine after all

  • by Lauran Neergaard

  • February 18, 2026

Related Content

Significant Burden of Respiratory Syncytial Virus Infection Detected in Older Adults in Swedish Long-Term Care Settings

FDA Expands ASCENIV Pediatric Use

Label change follows completion of required pediatric evaluation and updates prior age restrictions for treatment eligibility.

Medical Oddities: The Calmest Move in Cardiology?

Yoga for SVT, romantic brain bias, dog-made air chemistry, math learning clues, selenium tea, and glaucoma pillows—medicine’s weekly roundup of strange.